Online: | |
Visits: | |
Stories: |
Story Views | |
Now: | |
Last Hour: | |
Last 24 Hours: | |
Total: |
The National Cancer Institute’s page for Cannabis and Cannabinoids now lists several preclinical trials and studies in which the compounds have shown beneficial medical applications. While these merits come as no surprise for many, the real shocker here is Marijuana still being listed as a Schedule I substance in the eyes of the DEA.
The National Cancer Institute (NCI) is the United State’s primary agency in which cancer research and training is conducted. They are part of a larger umbrella of governmental agencies that comprise the Department of Health and Human Services (HHS). The NCI is largely responsible for the running the National Cancer Program, providing cancer-related information to the public, as well as developing programs and recommendations for the diagnosis, prevention, and treatment of cancer.
Now listed on the the NCI’s Cannabis and Cannabinoids page, which is assumed to be the United State’s official position regarding Marijuana’s potential application in treating cancer, are the following facts: